Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

Neuronix Seeks FDA Clearance For Alzheimer’s Therapy That Uses Transcranial Stimulation, Cognitive Training

On November 29, 2016, Neuronix Ltd. announced it had filed for clearance from the U.S. Food and Drug Administration (FDA) to market its neuroAD Therapy System, a transcranial stimulation therapy system that includes cognitive training as a treatment for mild to moderate Alzheimer’s disease. The filing was based on the strength of results from a multi-center clinical study on the safety and effectiveness of the system.

The study included 131 participants at nine medical centers in the United States and one in Israel. The researchers evaluated the safety and efficacy of the neuroAD Therapy System in comparison . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: